A pilot study evaluating the effectiveness of secukinumab in treating active non-segmental vitiligo did not find that IL-17 or Th17 cells had an exact role in the pathogenesis of vitiligo; however, it indicated that the balance of Th17/Th17.1/Th1 can change according to disease activity. Here, IL17A is linked to vitiligo.